- 10th Consecutive Year for MedImmune on the Fast 50 List -
GAITHERSBURG, Md., Sept. 29 /PRNewswire-FirstCall/ -- MedImmune, Inc. has
been named to Deloitte's Maryland Technology Fast 50 program for the tenth
consecutive year. The Technology Fast 50 is a ranking of the fastest growing
technology companies in the area by Deloitte & Touche LLP. Rankings are based
on the percentage growth over five years from 2001-2005.
"We are pleased to be recognized again by Deloitte & Touche as one of the
area's fastest growing technology companies," said Lota S. Zoth, MedImmune's
chief financial officer. "Our continued inclusion in the Fast 50 program
reflects the fact that MedImmune has doubled its revenues over the last five
years, reaching $1.2 billion in 2005. Our goal is to continue to grow our
business by aggressively investing in research and development activities.
Toward this end, during 2005 we completed several late-stage clinical trials,
started clinical testing on three new promising compounds, and expanded our
product portfolio with almost a dozen new targets.
"MedImmune's fast-paced growth continues in 2006," Zoth said. "We
submitted data to the FDA to expand our label indication for FluMist(R)
(Influenza Virus Vaccine Live, Intranasal); we entered into an agreement with
Infinity Pharmaceuticals to develop cancer drugs focused on two of the most
attractive targeted therapy opportunities in cancer research today; we
completed a Phase 3 study with our next-generation monoclonal antibody to
prevent respiratory syncytial virus (RSV); and we initiated clinical testing
with several new compounds, including those targeting lupus, RSV,
parainfluenza virus type 3, B-cell lymphomas, and avian influenza viruses. We
also received a $170-million contract from the U.S. Health and Human Services
Department to expedite development of cell culture-based production of our flu
vaccine, and earlier this month we broke ground on the first phase of a
planned 700,000 square-foot expansion of our cell culture manufacturing
facility in Frederick, Maryland."
"To rank on Deloitte's Technology Fast 50, companies must have phenomenal
revenue growth over five years," said Andrew Harrs, Deloitte's Southeast
regional managing partner for the Technology, Media and Telecommunications
Industry Practice. "MedImmune has proven to be one of the fast-growth success
stories in Maryland, and we applaud their dedication to making their vision a
The Maryland Technology Fast 50 program is presented by Deloitte and
sponsored by Wilmer Cutler Pickering Hale and Dorr, NASDAQ and UK Trade &
Investment. Media sponsors include PR Newswire and Washington SmartCEO
To qualify for the Technology Fast 50, companies must have had operating
revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered
in North America, and be a company that owns proprietary technology that
contributes to a significant portion of the company's operating revenues; or
devotes a significant proportion of revenues to the research and development
Winners of the 16 regional Technology Fast 50 programs in the United
States and Canada are automatically entered in Deloitte's Technology Fast 500
program, which ranks North America's top 500 fastest growing technology,
media, telecommunications and life sciences companies. For more information on
the Technology Fast 50 or Technology Fast 500 programs, visit
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,400 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss
Verein, its member firms and their respective subsidiaries and affiliates. As
a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its
member firms has any liability for each other's acts or omissions. Each of the
member firms is a separate and independent legal entity operating under the
names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other
related names. Services are provided by the member firms or their subsidiaries
or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche
Tohmatsu. In the U.S., services are provided by the subsidiaries of Deloitte &
Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte
Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and
not by Deloitte & Touche USA LLP.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts will
succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
CONTACT: Media: Kate Barrett, +1-301-398-4320, Investors: Peter Vozzo,
+1-301-398-4358, both of MedImmune, Inc.